

MAEKFDCHYCRDP
LQGKKYVQKDGHHCCLKCFD
KFCANTCVERKPIGADSKE
VHYKNRFWHDTCFRCAKCLQ
PLANETFCGGQQQRSCAQCT
TXEDFPKCKGCFKAIVAGDQ
NVEYKGTVWHKDCFTCSNCK
QVIGTGSFFPKGEDFYCVTC
HETKLAKHCVKCNKAITSGG
ITYQDQPWHADCFVCVTC SK
KLAGQRFTAIVEDQYYCVDCY
KNFVAKKCAGCKNPI TGF G K
GSSVVAYEGQSWHDYCFHCK
KCSVNLANKR FV FHQEQVYC
PDCAKKL

IN THE CLAIMS:

Please amend claims 1 and 13 as follows:

1. (Twice Amended) A method of identifying an agent that regulates the transcriptional activating activity of human AR or ER β , comprising:

contacting a cell expressing human androgen receptor (AR) or human estrogen receptor β (ER β), and, human skeletal muscle LIM protein (SLIM)3 with a test agent; and
determining whether said test agent regulates the transcriptional activating activity of human AR or human ER β .

13. (Amended) A method of identifying an agent that regulates the transcriptional activity of human AR or ER β , comprising:

contacting a cell expressing human AR or human ER β , and human SLIM, or biologically active polypeptides having at least 90% sequence identity thereto, with a test agent; and

determining whether said test agent regulates the transcriptional activating activity of human AR or ER β .

Please add the following new claims:

--16. A method of identifying an agent that regulates the transcriptional activating activity of human AR or ER β , comprising:

contacting with a test agent a cell expressing human androgen receptor (AR) or human estrogen receptor (ER β) and human skeletal muscle LIM protein (SLIM)3; or a modification thereof in which 1-10 amino acids of SLIM-3 are deleted and which is active in the regulation of transcriptional activation of human AR or ER β ; and

determining whether said test agent regulates the transcriptional activating activity of the human AR or human ER β .

17. A method of identifying an agent that regulates the transcriptional activity of human AR, comprising:

contacting a cell expressing human AR and human SLIM-3, or biologically active polypeptides having at least 90% sequence identity thereto, with a test agent; and

determining whether said test agent regulates the transcriptional activating activity of the human AR.

18. The method of claim 16, wherein said agent is a ligand that binds to SLIM-3 and/or to AR.

19. The method of claim 18, wherein the ligand is an agonist.

20. The method of claim 18, wherein the ligand is an antagonist.

21. The method of claim 17, wherein said agent is a ligand that binds to SLIM-3 and/or to AR.

22. The method of claim 21, wherein the ligand is an agonist.

23. The method of claim 21, wherein the ligand is an antagonist.--